Effect of Prophylactic Medical Compression Therapy on the Reduction of Breast Cancer-related Lymphedema in Patients With Adjuvant Docetaxel Chemotherapy: a Randomized Controlled Study
Launched by SAMSUNG MEDICAL CENTER · Mar 3, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether wearing special medical compression garments can help reduce the risk and severity of lymphedema in breast cancer patients who are receiving a type of chemotherapy called docetaxel. Lymphedema is a condition that can cause swelling in the arms after surgery to remove lymph nodes, which is often done during breast cancer treatment. Researchers want to see if these compression garments can make a difference for patients who have had surgery and are about to start their chemotherapy.
To participate in this study, patients need to be between the ages of 19 and 70 and have had surgery for breast cancer that involved removing lymph nodes. They should also be scheduled to receive docetaxel chemotherapy after their surgery. Participants will wear the compression garments as part of the trial and will be monitored to see how effective this treatment is. It’s important to note that some patients, such as those who have had prior breast surgeries or certain health conditions, may not be eligible to join. Overall, this study aims to find a way to help patients manage and potentially prevent lymphedema during their cancer treatment journey.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients who underwent radical mastectomy and sentinel lymphctomy or axillary lymphectomy after diagnosis of unilateral breast cancer
- • 2. Patients who are scheduled for adjuvant chemotherapy including Docetaxel after surgery
- • 3. Patients aged 19 to 70
- • 4. Patients who can understand the contents of this study and obtain consent
- Exclusion Criteria:
- • 1. Patients with a history of breast-related surgery prior to this breast cancer surgery
- • 2. Patients with metastases to other organs
- • 3. Patients who have undergone neoadjuvant chemotherapy or have previously received radiation therapy
- • 4. Patients with systemic diseases that may not be able to conduct clinical research
- • 5. Patients with skin diseases who cannot receive medical compression treatment
About Samsung Medical Center
Samsung Medical Center (SMC) is a leading healthcare institution in South Korea, renowned for its commitment to advancing medical research and innovation. As a prominent clinical trial sponsor, SMC integrates cutting-edge technology and expert clinical practices to conduct rigorous studies aimed at improving patient outcomes. The center is dedicated to fostering collaborations with global research entities and adhering to the highest ethical standards, ensuring the integrity and reliability of its clinical trials. With a focus on diverse therapeutic areas, SMC plays a pivotal role in translating scientific discoveries into effective treatments, ultimately enhancing the quality of healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
JIHYE HWANG, Professor
Study Chair
Physical & Rehabilitation Medicine Samsung Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials